Inactive Instrument

Analyst Reco. Tandem Diabetes Care Inc Nasdaq

Equities

US8753721047

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

UBS Adjusts Price Target on Tandem Diabetes Care to $40 From $28, Maintains Neutral Rating	03/05	MT
Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target is $45	29/04	MT
Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45	25/04	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $40 From $37, Maintains Buy Rating	23/04	MT
Stifel Upgrades Tandem Diabetes Care to Buy From Hold, Adjusts Price Target to $37 From $24	26/03	MT
Citigroup Raises Price Target on Tandem Diabetes Care to $31 From $25, Keeps Neutral Rating	15/03	MT
UBS Raises Tandem Diabetes Care Price Target to $28 From $18, Maintains Neutral Rating	22/01	MT
TD Cowen Raises Tandem Diabetes Care Price Target to $35 From $22, Maintains Outperform Rating	18/01	MT
BofA Securities Cuts Price Target on Tandem Diabetes Care to $18 From $33, Keeps Underperform Rating	18/23/18	MT
Citigroup Cuts Tandem Diabetes Care's Price Target to $23 From $31, Keeps Neutral Rating	02/23/02	MT
Jefferies Adjusts Price Target on Tandem Diabetes Care to $45 From $47, Maintains Buy Rating	02/23/02	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $31 From $33, Maintains Neutral Rating	21/23/21	MT
Baird Trims Price Target on Tandem Diabetes Care to $32 From $33, Maintains Neutral Rating	21/23/21	MT
UBS Adjusts Tandem Diabetes Care Price Target to $32 From $30, Maintains Neutral Rating	07/23/07	MT
Barclays Adjusts Price Target on Tandem Diabetes Care to $62 From $71, Keeps Overweight Rating	07/23/07	MT
Baird Adjusts Price Target on Tandem Diabetes Care to $33 From $38, Maintains Neutral Rating	04/23/04	MT
Citigroup Downgrades Tandem Diabetes Care to Neutral From Buy, Adjusts Price Target to $33 From $45	04/23/04	MT
UBS Adjusts Tandem Diabetes Care Price Target to $30 From $45, Maintains Neutral Rating	14/23/14	MT
Craig Hallum Adjusts Tandem Diabetes Care Price Target to $50 From $74, Maintains Buy Rating	13/23/13	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $45 From $55, Keeps Buy Rating	05/23/05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Tandem Diabetes Care Inc Nasdaq

Equities

US8753721047

Analyst Reco.

Filters